Latest filing published 11 May 2023 for ACELYRIN, Inc., €20.5M.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Westlake BioPartners Fund II, L.P.: trading record in brief
Westlake BioPartners Fund II, L.P. discloses dealings in ACELYRIN, Inc. to SEC (Form 4). Activity is concentrated on a single trading day, 9 May 2023, with 2 filings.
The open-market record is one-sided, with 1 purchase worth €20.5M and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
The latest filing, published on 11 May 2023, reports an open-market purchase of €20.5M in ACELYRIN, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Westlake BioPartners Fund II, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,250,000 shares@ US$18.00100.0% of flowCommon StockSEC:0001209191-23-028886:1Canonical exit: 7 Aug 2023 (T+90)
- 8,540,729 sharesCommon StockSEC:0001209191-23-028886:0
2 of 2 declarations
